- Home
- STTK vs TRVG Comparison
STTK vs TRVG Comparison
Compare STTK & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TRVG
- Stock Information
- Founded
- STTK 2016
- TRVG 2005
- Country
- STTK United States
- TRVG Germany
- Employees
- STTK N/A
- TRVG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TRVG EDP Services
- Sector
- STTK Health Care
- TRVG Technology
- Exchange
- STTK Nasdaq
- TRVG Nasdaq
- Market Cap
- STTK 83.8M
- TRVG 278.1M
- IPO Year
- STTK 2020
- TRVG N/A
- Fundamental
- Price
- STTK $2.08
- TRVG $3.35
- Analyst Decision
- STTK Hold
- TRVG Buy
- Analyst Count
- STTK 6
- TRVG 4
- Target Price
- STTK $2.67
- TRVG $4.50
- AVG Volume (30 Days)
- STTK 1.5M
- TRVG 64.3K
- Earning Date
- STTK 11-13-2025
- TRVG 11-04-2025
- Dividend Yield
- STTK N/A
- TRVG N/A
- EPS Growth
- STTK N/A
- TRVG N/A
- EPS
- STTK N/A
- TRVG N/A
- Revenue
- STTK $2,997,000.00
- TRVG $592,176,160.00
- Revenue This Year
- STTK N/A
- TRVG $18.39
- Revenue Next Year
- STTK N/A
- TRVG $11.42
- P/E Ratio
- STTK N/A
- TRVG N/A
- Revenue Growth
- STTK N/A
- TRVG 7.39
- 52 Week Low
- STTK $0.69
- TRVG $1.60
- 52 Week High
- STTK $3.95
- TRVG $5.83
- Technical
- Relative Strength Index (RSI)
- STTK 71.77
- TRVG 51.28
- Support Level
- STTK $1.68
- TRVG N/A
- Resistance Level
- STTK $2.01
- TRVG $3.39
- Average True Range (ATR)
- STTK 0.22
- TRVG 0.13
- MACD
- STTK 0.07
- TRVG -0.09
- Stochastic Oscillator
- STTK 98.23
- TRVG 94.73
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TRVG trivago N.V.
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.